13 September 2017
Novel Genetic Mutation Discovered in Parkinson’s Disease Patient
According to a new report in the Journal of Parkinson’s Disease, researchers identified the first case of a patient with Parkinson's disease carrying a mutation in the ACMSD gene.
31 July 2017
Two New Studies Offer Insights into Gastrointestinal Dysfunction in Parkinson’s Patients
Constipation is one of the most common non-motor related complaints affecting Parkinson’s disease (PD) patients.
23 March 2017
Exercising 2.5 Hours Per Week Associated with Slower Declines in Parkinson’s Disease Patients
Parkinson’s disease (PD) is a progressive condition that often results in mobility impairments and can lead to decreased health-related quality of life (HRQL) and death. There is evidence that physical activity can delay decline in PD patients.
23 March 2017
Journal of Parkinson’s Disease Celebrates Key Breakthroughs that Shaped PD Research over the Last 200 Years
Marking the 200th anniversary of James Parkinson’s first published description of the disease that would come to bear his name, the Journal of Parkinson’s Disease is proud to publish
7 March 2017
Extended Use of MAO-B Inhibitors Slows Decline in Parkinson’s Disease Patients
There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson’s disease (PD) and improve long-term outcomes. They have shown neuroprotective effects in cell culture and animal studies of PD, but clinical trial results have been mixed and have failed to convincingly demonstrate disease modifying effects in people with PD. In a retrospective analysis by Hauser et al. in the Journal of Parkinson’s Disease, researchers looked at the results from a large study and found that participants who received an MAO-B inhibitor for a longer period of time experienced slower clinical decline.
13 February 2017
Altmetric Data Analysis Reveals How Parkinson’s Disease Research Affects the World
ÜberResearch and Altmetric, leading data and analytics companies serving scientific funders and research organizations, have published an analysis of Parkinson’s disease research papers with the highest Altmetric Attention Scores in the Journal of Parkinson’s Disease. The publication is the first in a series aimed at utilizing Altmetric data to provide a more nuanced understanding of how the announcements of new medical discoveries affect the wide-range of disease-specific stakeholders including researchers, funders, care providers, and patients.
15 November 2016
Hospital Admissions Rising for Elderly Patients with Parkinson’s Disease
Although treatment for Parkinson’s disease (PD) is significantly extending the lives of patients, these patients are now being admitted to hospitals at increasing rates. In a study reported in the Journal of Parkinson’s Disease, researchers in Ireland have found that the top five reasons for hospital admission of PD patients are urinary tract infections, pneumonia, lower respiratory tract infections, aspiration pneumonia and femur fracture. More troubling is the stark increase in PD patients requiring long-term nursing home care on discharge, with 27% of the over 65 group discharged to a nursing home compared to 12% admitted from a nursing home.
15 November 2016
Parkinson’s Disease Patients Benefit from Physical Activity
A comprehensive review published in the Journal of Parkinson’s Disease confirms that people living with Parkinson’s disease (PD) can benefit from being physically active, especially when it comes to improving gait and balance, and reducing risks of falls. It concludes that health professionals should be confident about prescribing physical activity to improve the health and quality of life of PD patients.
12 July 2016
Leukemia Drug Shows Early Promise for Treating Parkinson’s Disease and Dementia
Parkinson’s disease (PD) is the second most common neurodegenerative disorder that causes a range of motor and non-motor symptoms. During the course of the disease, dopamine (DA)-producing neurons are lost and bundles of proteins known as Lewy bodies (LBs) form in the brain. A study reported in the Journal of Parkinson’s Disease provided molecular evidence that the FDA-approved leukemia drug nilotinib may restore brain dopamine and reduce toxic proteins associated with LB formation in PD and dementia patients.
Pages
